BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31873875)

  • 1. DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.
    Umemura Y; Wang D; Peck KK; Flynn J; Zhang Z; Fatovic R; Anderson ES; Beal K; Shoushtari AN; Kaley T; Young RJ
    J Neurooncol; 2020 Jan; 146(2):339-346. PubMed ID: 31873875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
    Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
    AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudoprogression of Melanoma Brain Metastases.
    Simard JL; Smith M; Chandra S
    Curr Oncol Rep; 2018 Nov; 20(11):91. PubMed ID: 30413981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
    Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
    Bhatia A; Birger M; Veeraraghavan H; Um H; Tixier F; McKenney AS; Cugliari M; Caviasco A; Bialczak A; Malani R; Flynn J; Zhang Z; Yang TJ; Santomasso BD; Shoushtari AN; Young RJ
    Neuro Oncol; 2019 Dec; 21(12):1578-1586. PubMed ID: 31621883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.
    Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.
    Urban H; Steidl E; Hattingen E; Filipski K; Meissner M; Sebastian M; Koch A; Strzelczyk A; Forster MT; Baumgarten P; Ronellenfitsch MW; Steinbach JP; Voss M
    Front Immunol; 2021; 12():798811. PubMed ID: 35046955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pseudoprogression in immune therapy].
    de Boer FJ; Stigt JA; Netters FJS; Koornstra RHT; Tije AJT; de Groot JWB
    Ned Tijdschr Geneeskd; 2019 Jul; 163():. PubMed ID: 31283128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
    Le Rhun E; Wolpert F; Fialek M; Devos P; Andratschke N; Reyns N; Regli L; Dummer R; Mortier L; Weller M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32747372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical management of melanoma brain metastases in patients treated with immunotherapy.
    Lonser RR; Song DK; Klapper J; Hagan M; Auh S; Kerr PB; Citrin DE; Heiss JD; Camphausen K; Rosenberg SA
    J Neurosurg; 2011 Jul; 115(1):30-6. PubMed ID: 21476810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
    Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
    Hatzoglou V; Yang TJ; Omuro A; Gavrilovic I; Ulaner G; Rubel J; Schneider T; Woo KM; Zhang Z; Peck KK; Beal K; Young RJ
    Neuro Oncol; 2016 Jun; 18(6):873-80. PubMed ID: 26688076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-Small Cell Lung Cancer.
    Akhoundova D; Hiltbrunner S; Mader C; Förster R; Kraft J; Schwanhäusser B; Bankel L; Kollias S; Treyer V; Rushing EJ; Lee SY; Andratschke N; Hüllner M; Curioni-Fontecedro A
    Clin Nucl Med; 2020 Feb; 45(2):113-117. PubMed ID: 31876831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.